Investor Presentation Q1 2023
118
Investor presentation
First three months of 2023
Rest of World at a glance
Diabetes trend in population
Million
21%
DKK
billion
300
250
80
18%
200
60
150
286
40
227
40
100
187
50
20
20
0
2021
2030
Population with diabetes
Diabetes growth rate
2045
Diabetes market by value and
Novo Nordisk market share
Rest of World
Novo Nordisk reported sales
First quarter of
2023
Sales
(MDKK)
Growth²
Total GLP-13
2,436
40%
80%
Long-acting insulin4
665
14%
Premix insulin5
622
-2%
60
34%1
GLP-1
Fast-acting insulin
544
-5%
60%
Human insulin
748
8%
2%1
Insulin
Total insulin
2,579
4%
40%
Other Diabetes care?
114
-40%
Diabetes care
5,129
17%
5%1
20%
Obesity care8
662
57%
OAD
Diabetes & Obesity
5,791
20%
0
0%
care
Feb
2018
Feb
2023
Rare disease⁹
Total
1,076
-27%
6,867
9%
GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Feb 2023: Novo Nordisk 58%, Sanofi
24% and Eli Lilly 13%; Competitor GLP-1 value market shares, as of Feb 2023: Novo
Nordisk 76%, Eli Lilly 24% and AstraZeneca 0.3%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Feb 2023 value
figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMixⓇ and
RyzodegⓇ 6 Comprises NovoRapidⓇ and FiaspⓇ:7 Comprises NovoNormⓇ and
needles;; 8 Comprises SaxendaⓇ: 9 Comprises primarily Esperoct®, Refixia®
,NovoSeven®, Novo Eight® and Norditropin®View entire presentation